methylphenidate hydrochloride

FDA Drug Profile — RELEXXII, METADATE CD, methylphenidate hydrochloride, QuilliChew ER, APTENSIO XR

Drug Details

Generic Name
methylphenidate hydrochloride
Brand Names
RELEXXII, METADATE CD, methylphenidate hydrochloride, QuilliChew ER, APTENSIO XR, Methylphenidate Hydrochloride Extended-Release, Ritalin LA, Quillivant XR, Ritalin, methylphenidate hydrochloride CD
Application Number
NDA216117
Sponsor
Societal CDMO Gainesville, LLC
NDC Codes
50
Dosage Forms
CAPSULE, EXTENDED RELEASE, TABLET, EXTENDED RELEASE, TABLET, CHEWABLE, EXTENDED RELEASE, SUSPENSION, EXTENDED RELEASE, TABLET
Routes
ORAL
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14 )]. Limitations of Use The use of dexmethylphenidate hydrochloride extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.7) , Use in Specific Populations (8.4) ] . Dexmethylphenidate hydrochloride extended-release capsules are a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) ( 1 ). Limitations of Use The use of dexmethylphenidate hydrochloride extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.7 , 8.4 ).